This Week at FDA: Pediatric use for Lilly’s COVID mAbs; Will Woodcock stay on?
Regulatory NewsMichael Mezher • Kari Oakes
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMichael Mezher • Kari OakesBiologics/ biosimilars/ vaccinesDiagnostics/IVDsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy